BRNS VS ONCY Stock Comparison

Performance

BRNS
10/100

BRNS returned -42.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

ONCY
100/100

ONCY returned 23.10% in the last 12 months. Based on SPY's performance of -20.75%, its performance is above average giving it a score of 100 of 100.

Earnings

BRNS
100/100

BRNS has missed earnings 1 times in the last 20 quarters.

ONCY
17/100

ONCY has missed earnings 5 times in the last 20 quarters.

Volatility

BRNS
50/100

BRNS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

ONCY
48/100

ONCY has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

Sentiment

BRNS

"Sentiment" not found for BRNS

ONCY
68/100

ONCY had a bullish sentiment score of 68.25% across Twitter and StockTwits over the last 12 months. It had an average of 14.05 posts, 21.23 comments, and 43.15 likes per day.

Technicals

BRNS

"Technicals" not found for BRNS

ONCY
14/100

ONCY receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Profit

BRNS

"Profit" not found for BRNS

ONCY
10/100

Out of the last 20 quarters, ONCY has had 1 profitable quarters and has increased their profits year over year on 1 of them.

All score calculations are broken down here to help you make more informed investing decisions

Barinthus Biotherapeutics plc American Depositary Shares Summary

Nasdaq / BRNS

Healthcare

Biotechnology

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Oncolytics Biotech, Inc. Common Shares Summary

Nasdaq / ONCY

Healthcare

Biotechnology

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Power up your portfolio